Randomized multicenter phase II study evaluating two dosing schedules of TG4010 (MVA-MUC1-IL2) in patients with adenocarcinoma of the prostate
Latest Information Update: 03 Nov 2021
At a glance
- Drugs TG 4010 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Nov 2006 Status change
- 11 Nov 2005 New trial record.